BT7 is a modern hybrid-indica strain developed through the crossing of Tangie and The OG #18. This cultivar is categorized as a moderate-difficulty plant suitable for cultivation in both indoor and outdoor environments. Growers can expect a high yield from this variety, which reaches maturity after a 58-day flowering cycle. Its genetic significance is solidified by its status as the parent of the strain known as Seats Taken.

The chemical profile of BT7 is defined by a complex range of terpenes, led by a dominant presence of caryophyllene followed by limonene, myrcene, bisabolol, guaiol, and linalool. Lesser concentrations of humulene, valencene, beta-pinene, isopulegol, pinene, terpinolene, nerolidol, caryophyllene-oxide, gamma-terpinene, camphene, alpha-terpinene, borneol, ocimene, geraniol, sabinene, p-cymene, and eucalyptol further round out the aromatic and flavor composition. This multifaceted terpene structure contributes to the nuanced sensory profile of the flower.

As a THC-dominant cultivar, BT7 provides primary effects that are characterized by a sense of relaxation, calm, and focus. These properties make the strain a suitable choice for users seeking support for pain, stress, and sleep. Its established role in the lineage of modern cannabis genetics continues through its notable offspring, maintaining its utility for those requiring a balanced, THC-heavy experience.